Quick answer: when GLP 1 therapy is and is not the right tool GLP 1 therapy can be a strong option when menopause weight gain is tied to insulin resistance, appetite dysregulation, visceral fat gain, or repeated plateaus despite consistent habits
For example, a patient whos been on semaglutide for six months or more may have significantly reduced alcohol consumption or stopped smoking spontaneously, outside any formal program, in a way that felt entirely unremarkable to them
As such, they may overlook symptoms that individuals find bothersome but less dangerous, or that occur less frequently
Higher doses (2040 mg/kg) should not exceed 6 months
In type 2 diabetics, the risk of first heart failure hospitalization was 31% lower in the omega-3-supplemented group compared with the placebo group